Skip to main content
SpringerLink
Log in

Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP)

Updated Results of a Randomized Study

  • Chapter
Drug Resistance in Leukemia and Lymphoma III

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 457))

Abstract

We designed a randomized trial of IC with or without quinine, an agent capable of reverting the multidrug resistance (mdr) phenotype, in patients aged < 65 years with high risk MDS. Patients were randomized to receive Mitoxantrone 12mg/m2/d d2–5 + AraC 1g/m2/12h d1–5, with (Q+) or without (Q) quinine (30mg/kg/day). 131 patients were included. PGP expression analysis was successfully made in 91 patients and 42 patients (46%) had positive PGP expression. In PGP positive cases, 13 of the 25 (52%) patients who received quinine achieved CR, as compared to 3 of the 17 (18%) patients treated with chemotherapy alone (p=0.02). In PGP negative cases, the CR rate was 35% and 49%, respectively in patients who received quinine or chemotherapy alone (difference not significant). In the 42 PGP positive patients, median Kaplan-Meier (KM) survival was 13 months in patients allocated to the quinine group, and 8 months in patients treated with chemotherapy alone (p=0.01). In PGP negative patients, median KM survival was 14 months in patients allocated to the quinine group, and 14 months in patients treated with chemotherapy alone. Side effects of quinine mainly included vertigo and tinnitus that generally disappeared with dose reduction. Mucositis was significantly more frequently observed in the quinine group. No life threatening cardiac toxicity was observed. In conclusion, results of this randomized study show that quinine increases the CR rate and survival in PGP positive MDS cases treated with IC. The fact that quinine had no effect on the response rate and survival of PGP negative MDS suggests a specific effect on PGP mediated drug resistance rather than, for instance, a simple effect on the metabolism of Mitoxantrone and/or AraC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Martiat P., Ferrant A., Michaux J.L., Sokal G. (1988); Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematol Oncol, 6: 299–305.

    Article  PubMed  CAS  Google Scholar 

  2. Michels SD., McKenna RW., Arthur DC., Brunning RD. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65: 1364–1372.

    PubMed  CAS  Google Scholar 

  3. Hoyle C.F., De Bastos M., Wheatley K., Sherrington P.D., Fischer P.J., Rees J.K.H., Gray R., Hayhoe F.G.J. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC’s 9th AML trial. Br J Haematol, 72: 45–53.

    Article  PubMed  CAS  Google Scholar 

  4. De Witte T., Muus P., De Pauw B., Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831–837.

    Article  PubMed  Google Scholar 

  5. Fenaux P., Morel P., Rose C, Lai J.L., Jouet J.P., Bauters F. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol, 77, 497–501.

    Article  PubMed  CAS  Google Scholar 

  6. De Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., Jaksic J., Selleslag D., Zittoun R., Dardenne M., Solbu G., Zwierzina H., Muus P. (1995) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805–1811.

    PubMed  Google Scholar 

  7. Berstein S., Brunetto V., Davey F., Mayer RJ., Wurster-Hill D., Schiffer C., Bloomfield C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (suppl 1), 1960.

    Google Scholar 

  8. Ruutu T., Hänninen A., Järventie G., Koistinen P., Koivunen E., Kätkä K., Nousiainen T., Pelliniemi T.T., Remes K., Timonen T., Volin L., Elonen E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia subsequent to MDS with idarubicin and cytarabine (abstract). Br J Haematol, 87(suppl. 1): 19.

    Google Scholar 

  9. Aul C., Runde V., Germing U., Burk M., Heyll A., Hildebrandt B., Willers R. (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol, 70(suppl 2), A138.

    Google Scholar 

  10. Aul C., Runde V., Gattermann N., Germing U., Schneider W., (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. Leuk Res, 18, suppl: 22 (abstr).

    Article  Google Scholar 

  11. Hiddemann W., Büchner T., Wörmann B., Koch P., Aul C., Balleisen L., Bennet J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitox-antrone with or without GM-CSF (abstract). Ann Hematol, 70(suppl II): A109.

    Google Scholar 

  12. Gore S.D., Burke P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy (abstract). Blood, 86(suppl 1): 339a.

    Google Scholar 

  13. Wattel E., de Botton S., Laï J.L., Preudhomme C., Lepelley P., Bauters F., Fenaux P. (1997). Long term follow up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long survivors and outcome of partial responders. Br J Haematol, 98, 983–991.

    Article  PubMed  CAS  Google Scholar 

  14. Gardin C., Chaibi P., de Revel T., Rousselot P., Turlure P., Micléa J.M., Nédellec G., Dombret H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11: 16–21.

    Article  PubMed  CAS  Google Scholar 

  15. Lepelley P., Soenen V., Preudhomme C., Lai J.L., Cosson A., Fenaux P. (1994). Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998–1004.

    PubMed  CAS  Google Scholar 

  16. Bennis S., Ichas F., Robert J. (1995). Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer, 62, 283–290.

    Article  PubMed  CAS  Google Scholar 

  17. Dorr R.T., Liddil J.D. (1991). Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemother Pharmacol, 27, 290–294.

    Article  PubMed  CAS  Google Scholar 

  18. Genne P., Duchamp O., Solary E., Pinard D., Belon J.P., Dimanche-Boitrel M.T., Chauffert B. (1994). Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia, 8, 160–164.

    PubMed  CAS  Google Scholar 

  19. Malayeri R., Filipits M., Suchomel R.W., Z’chbauer S., Lechner K., Pirker R. (1996). Multidrug resistance in leukemias and its reversal. Leuk Lymphoma, 23, 451–458.

    Article  PubMed  CAS  Google Scholar 

  20. Solary E., Velay I., Chauffert B., Caillot D., Bidan J.M., Dumas M., Casasnovas O., Guy H. (1990). Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol, 32, 361–363.

    PubMed  CAS  Google Scholar 

  21. Sonneveld P. (1996). Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer, 6, 1062–1069.

    Article  Google Scholar 

  22. Wigler P.W., Patterson F.K. (1994). Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta, 1189, 1–6.

    Article  PubMed  CAS  Google Scholar 

  23. Pajeva I.K., Wiese M., Cordes H.P., Seydel J.K. (1996). Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol, 122, 27–40.

    Article  PubMed  CAS  Google Scholar 

  24. Solary E., Bidan J.M., Calvo F., Chauffert B., Caillot D., Mugneret F., Gauville C., Tsuruo T., Carli P.M., Guy H. (1991a). P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia, 5, 592–59

    PubMed  CAS  Google Scholar 

  25. Solary E., Velay I., Chauffert B., Bidan J.M., Caillot D., Dumas M., Guy H. (1991b). Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ ADM. Cancer, 68, 1714–1719.

    Article  PubMed  CAS  Google Scholar 

  26. Solary E., Caillot D., Chauffert B., Casasnovas R.O., Dumas M., Maynadie M., Guy H. (1992). Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol, 10, 1730–1736.

    PubMed  CAS  Google Scholar 

  27. Solary E., Witz B., Caillot D., Moreau P., Desablens B., Cahn J.Y., Sadoun A., Pignon B., Berthou C., Maloisel F., Guyotat D., Casassus, P, Ifrah N., Lamy Y., Audhuy B., Colombat P., Harousseau J.L. (1996). Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198–1205.

    PubMed  CAS  Google Scholar 

  28. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., Weick J.K., Willman C.L. (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1 +/efflux-cases. Blood, 86, 2329–2342.

    PubMed  CAS  Google Scholar 

  29. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. (1993). Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315–1323.

    PubMed  CAS  Google Scholar 

  30. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. (1990). Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer, 66, 868–873.

    Article  PubMed  CAS  Google Scholar 

  31. Wood P., Burgess R., MacGregor A., Yin J.A. (1994). P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol, 87, 509–514.

    Article  PubMed  CAS  Google Scholar 

  32. Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., et al. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol, 75, 340–345.

    Article  PubMed  CAS  Google Scholar 

  33. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473–476.

    PubMed  CAS  Google Scholar 

  34. Marie J.P., Legrand O., Russo D., Zhou D., Suberville A.M., Zittoun R. (1992). Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leuk Lymphoma, 8, 261–265.

    Article  PubMed  CAS  Google Scholar 

  35. Hegewisch-Becker S., Hossfeld D.K. (1996). The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol, 72, 105–117.

    Article  PubMed  CAS  Google Scholar 

  36. Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchai S., Witz F., Rose C., Guerci O. (1995). Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147–2153.

    PubMed  CAS  Google Scholar 

  37. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., et al. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia [see comments]. J Natl Cancer Inst, 83, 708–712.

    Article  PubMed  CAS  Google Scholar 

  38. Zöchbauer S., Gsur A., Brunner R., Kyrle P.A., Lechner K., Pirker R. (1994). P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia, 8, 974–977.

    PubMed  Google Scholar 

  39. List A.F. (1996). Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10, 937–942.

    PubMed  CAS  Google Scholar 

  40. McKenna S.L., Padua R.A. (1997). Multidrug resistance in leukaemia. BrJ Haematol, 96, 659–74.

    Article  CAS  Google Scholar 

  41. Gonzalez O., Colombo T., De Fusco M., Imperatori L., Zucchetti M., D’Incalci M. (1995). Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol, 36, 335–40.

    Article  PubMed  CAS  Google Scholar 

  42. Sonneveld P., Marie J.P., Huisman C., Vekhoff A., Schoester M., Faussat A.M., van Kapel J., Groenewegen A., Charnick S., Zittoun R., L’wenberg, B (1996). Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia, 10, 1741–1750.

    PubMed  CAS  Google Scholar 

  43. Weber D., Dimopoulos M., Sinicrope F., Alexanian R. (1995). VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma, 19, 159–163.

    Article  PubMed  CAS  Google Scholar 

  44. List A.F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier M., Dalton W. (1993). Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia [see comments]. J Clin Oncol, 11, 1652–60.

    PubMed  CAS  Google Scholar 

  45. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol, 9, 17–24.

    PubMed  CAS  Google Scholar 

  46. Wilson W.H., Bates S.E., Fojo A., Bryant G., Zhan Z., Regis J., Wittes R.E., Jaffe E.S., Steinberg S.M., Herdt J., et a. (1995). Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol, 13, 1995–2004.

    PubMed  CAS  Google Scholar 

  47. Genne P., Dimanche-Boitrel M.T., Mauvernay R.Y., Gutierrez G., Duchamp O., Petit J.M., Martin F., Chauffert B. (1992). Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res, 52, 2797–2801.

    PubMed  CAS  Google Scholar 

  48. Beck J., Niethammer D., Gekeler V. (1996). MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia, 10, S39–S45.

    PubMed  Google Scholar 

  49. Lepelley P., Grardel N., Preudhomme C., Wattel E., Cosson A., Fenaux P. (1998). Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS). Leuk Lymphoma, 29, 547–551.

    Article  PubMed  CAS  Google Scholar 

  50. Holmes J., Wareing C., Jacobs A., Hayes J.D., Padua R.A., Wolf C.R. (1990). Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. Br J Cancer, 62, 209–212.

    Article  PubMed  CAS  Google Scholar 

  51. Gieseler F., Glasmacher A., K‰mpfe D., Wandt H., Nuessler V., Valsamas S., Kunze J., Wilms K. (1996). Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia, 10, 1177–1180.

    PubMed  CAS  Google Scholar 

  52. Campos, L., Rouault, J.P, Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P & Guyotat, D. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091–3096.

    PubMed  CAS  Google Scholar 

  53. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148–3157.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS, France

    E. Wattel, E. Solary, B. Hecquet, D. Caillot, N. Ifrah, A. Brion, N. Milpied, M. Janvier, A. Guerci, H. Rochant, C. Cordonnier, F. Dreyfus, A. Veil, L. Hoang-Ngoc, A. M. Stoppa, N. Gratecos, A. Sadoun, H. Tilly, P. Brice, B. Lioure, B. Desablens, B. Pignon, J. P. Abgrall, M. Leporrier, B. Dupriez, D. Guyotat, P. Lepelley & Pr. P. Fenaux

  2. Service des Maladies du Sang, CHU, 1 place de Verdun, 59037, Lille, France

    Pr. P. Fenaux

Authors
  1. E. Wattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Solary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Hecquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Caillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Brion
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Janvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Guerci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Rochant
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. Cordonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Dreyfus
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Veil
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. L. Hoang-Ngoc
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A. M. Stoppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. N. Gratecos
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A. Sadoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H. Tilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. P. Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. B. Lioure
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. B. Desablens
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. B. Pignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. J. P. Abgrall
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. M. Leporrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. B. Dupriez
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. D. Guyotat
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. P. Lepelley
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Pr. P. Fenaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    G. J. L. Kaspers , R. Pieters  & A. J. P. Veerman ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wattel, E. et al. (1999). Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP). In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4811-9_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7180-9

  • Online ISBN: 978-1-4615-4811-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation